U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Measurable Residual Disease

MedGen UID:
66115
•Concept ID:
C0242596
•
Neoplastic Process
Synonyms: Minimal Disease, Residual; Minimal Residual Disease; Minimal Residual Diseases; Neoplasm, Residual; Residual Disease, Minimal; Residual Minimal Disease; Residual Minimal Diseases; Residual Neoplasm; Residual Neoplasms

Definition

Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMeasurable Residual Disease

Professional guidelines

PubMed

Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.
Falini B, Dillon R
Blood Cancer Discov 2024 Jan 8;5(1):8-20. doi: 10.1158/2643-3230.BCD-23-0144. PMID: 37917833Free PMC Article
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.
Shimony S, Stahl M, Stone RM
Am J Hematol 2023 Mar;98(3):502-526. Epub 2023 Jan 13 doi: 10.1002/ajh.26822. PMID: 36594187
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B
Blood 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867. PMID: 35797463

Recent clinical studies

Etiology

Hairy Cell Leukemia: Where Are We in 2023?
Mendez-Hernandez A, Moturi K, Hanson V, Andritsos LA
Curr Oncol Rep 2023 Aug;25(8):833-840. Epub 2023 Apr 25 doi: 10.1007/s11912-023-01419-z. PMID: 37097545Free PMC Article
Acute myeloid leukaemia.
DiNardo CD, Erba HP, Freeman SD, Wei AH
Lancet 2023 Jun 17;401(10393):2073-2086. Epub 2023 Apr 15 doi: 10.1016/S0140-6736(23)00108-3. PMID: 37068505
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.
Shimony S, Stahl M, Stone RM
Am J Hematol 2023 Mar;98(3):502-526. Epub 2023 Jan 13 doi: 10.1002/ajh.26822. PMID: 36594187
Roadmap to cure multiple myeloma.
Rodriguez-Otero P, Paiva B, San-Miguel JF
Cancer Treat Rev 2021 Nov;100:102284. Epub 2021 Aug 31 doi: 10.1016/j.ctrv.2021.102284. PMID: 34597912
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ
Blood 2018 Mar 22;131(12):1275-1291. Epub 2018 Jan 12 doi: 10.1182/blood-2017-09-801498. PMID: 29330221Free PMC Article

Diagnosis

Hairy Cell Leukemia: Where Are We in 2023?
Mendez-Hernandez A, Moturi K, Hanson V, Andritsos LA
Curr Oncol Rep 2023 Aug;25(8):833-840. Epub 2023 Apr 25 doi: 10.1007/s11912-023-01419-z. PMID: 37097545Free PMC Article
Acute myeloid leukaemia.
DiNardo CD, Erba HP, Freeman SD, Wei AH
Lancet 2023 Jun 17;401(10393):2073-2086. Epub 2023 Apr 15 doi: 10.1016/S0140-6736(23)00108-3. PMID: 37068505
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.
Shimony S, Stahl M, Stone RM
Am J Hematol 2023 Mar;98(3):502-526. Epub 2023 Jan 13 doi: 10.1002/ajh.26822. PMID: 36594187
Roadmap to cure multiple myeloma.
Rodriguez-Otero P, Paiva B, San-Miguel JF
Cancer Treat Rev 2021 Nov;100:102284. Epub 2021 Aug 31 doi: 10.1016/j.ctrv.2021.102284. PMID: 34597912
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ
Blood 2018 Mar 22;131(12):1275-1291. Epub 2018 Jan 12 doi: 10.1182/blood-2017-09-801498. PMID: 29330221Free PMC Article

Therapy

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F
J Clin Oncol 2024 May 1;42(13):1499-1508. Epub 2024 Jan 26 doi: 10.1200/JCO.23.01911. PMID: 38277619Free PMC Article
How I treat refractory and relapsed acute myeloid leukemia.
Thol F, Döhner H, Ganser A
Blood 2024 Jan 4;143(1):11-20. doi: 10.1182/blood.2023022481. PMID: 37944143
Acute myeloid leukaemia.
DiNardo CD, Erba HP, Freeman SD, Wei AH
Lancet 2023 Jun 17;401(10393):2073-2086. Epub 2023 Apr 15 doi: 10.1016/S0140-6736(23)00108-3. PMID: 37068505
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.
Shimony S, Stahl M, Stone RM
Am J Hematol 2023 Mar;98(3):502-526. Epub 2023 Jan 13 doi: 10.1002/ajh.26822. PMID: 36594187
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B
Blood 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867. PMID: 35797463

Prognosis

Hairy Cell Leukemia: Where Are We in 2023?
Mendez-Hernandez A, Moturi K, Hanson V, Andritsos LA
Curr Oncol Rep 2023 Aug;25(8):833-840. Epub 2023 Apr 25 doi: 10.1007/s11912-023-01419-z. PMID: 37097545Free PMC Article
Acute myeloid leukaemia.
DiNardo CD, Erba HP, Freeman SD, Wei AH
Lancet 2023 Jun 17;401(10393):2073-2086. Epub 2023 Apr 15 doi: 10.1016/S0140-6736(23)00108-3. PMID: 37068505
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.
Shimony S, Stahl M, Stone RM
Am J Hematol 2023 Mar;98(3):502-526. Epub 2023 Jan 13 doi: 10.1002/ajh.26822. PMID: 36594187
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B
Blood 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867. PMID: 35797463
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, Tettero JM, Bachas C, Baer C, Béné MC, Bücklein V, Czyz A, Denys B, Dillon R, Feuring-Buske M, Guzman ML, Haferlach T, Han L, Herzig JK, Jorgensen JL, Kern W, Konopleva MY, Lacombe F, Libura M, Majchrzak A, Maurillo L, Ofran Y, Philippe J, Plesa A, Preudhomme C, Ravandi F, Roumier C, Subklewe M, Thol F, van de Loosdrecht AA, van der Reijden BA, Venditti A, Wierzbowska A, Valk PJM, Wood BL, Walter RB, Thiede C, Döhner K, Roboz GJ, Cloos J
Blood 2021 Dec 30;138(26):2753-2767. doi: 10.1182/blood.2021013626. PMID: 34724563Free PMC Article

Clinical prediction guides

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD
Blood Cancer Discov 2023 Jul 5;4(4):276-293. doi: 10.1158/2643-3230.BCD-22-0205. PMID: 37102976Free PMC Article
Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.
Tiong IS, Loo S
Int J Mol Sci 2023 Mar 1;24(5) doi: 10.3390/ijms24054790. PMID: 36902217Free PMC Article
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
Saygin C, Cannova J, Stock W, Muffly L
Haematologica 2022 Dec 1;107(12):2783-2793. doi: 10.3324/haematol.2022.280638. PMID: 36453516Free PMC Article
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Döhner H
J Clin Oncol 2022 Mar 10;40(8):855-865. Epub 2021 Dec 15 doi: 10.1200/JCO.21.01546. PMID: 34910556Free PMC Article
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, Tettero JM, Bachas C, Baer C, Béné MC, Bücklein V, Czyz A, Denys B, Dillon R, Feuring-Buske M, Guzman ML, Haferlach T, Han L, Herzig JK, Jorgensen JL, Kern W, Konopleva MY, Lacombe F, Libura M, Majchrzak A, Maurillo L, Ofran Y, Philippe J, Plesa A, Preudhomme C, Ravandi F, Roumier C, Subklewe M, Thol F, van de Loosdrecht AA, van der Reijden BA, Venditti A, Wierzbowska A, Valk PJM, Wood BL, Walter RB, Thiede C, Döhner K, Roboz GJ, Cloos J
Blood 2021 Dec 30;138(26):2753-2767. doi: 10.1182/blood.2021013626. PMID: 34724563Free PMC Article

Recent systematic reviews

Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis.
Rios-Olais FA, McGary AK, Tsang M, Almader-Douglas D, Leis JF, Buras MR, Hilal T
JAMA Oncol 2024 Sep 1;10(9):1221-1227. doi: 10.1001/jamaoncol.2024.2122. PMID: 38990562Free PMC Article
Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis.
Short NJ, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Gonzalez GN, Hwang H, Qi X, Kantarjian H, Zhou S, Ravandi F
Leukemia 2022 Dec;36(12):2817-2826. Epub 2022 Oct 19 doi: 10.1038/s41375-022-01692-0. PMID: 36261575
Measurable residual disease in pediatric acute myeloid leukemia: a systematic review.
Segerink WH, de Haas V, Kaspers GJL
Expert Rev Anticancer Ther 2021 Apr;21(4):451-459. Epub 2021 Mar 11 doi: 10.1080/14737140.2021.1860763. PMID: 33706635
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.
Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Nogueras Gonzalez G, Hwang H, Qi X, Kantarjian H, Ravandi F
JAMA Oncol 2020 Dec 1;6(12):1890-1899. doi: 10.1001/jamaoncol.2020.4600. PMID: 33030517Free PMC Article
A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia.
Bassan R, Brüggemann M, Radcliffe HS, Hartfield E, Kreuzbauer G, Wetten S
Haematologica 2019 Oct;104(10):2028-2039. Epub 2019 Mar 19 doi: 10.3324/haematol.2018.201053. PMID: 30890593Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...